Sign In
Buy PCVX
$51.96
-0.150 (-0.288%)
At Close: Jun 23, 2026
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
03:39pm, Monday, 31'st Mar 2025
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
08:56am, Monday, 31'st Mar 2025
Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
07:00am, Monday, 31'st Mar 2025
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immun
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
05:00pm, Sunday, 30'th Mar 2025
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript
03:26am, Wednesday, 26'th Feb 2025
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Con
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:01pm, Tuesday, 25'th Feb 2025
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
04:05pm, Wednesday, 12'th Feb 2025
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
08:00am, Wednesday, 05'th Feb 2025
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenic
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
04:05pm, Thursday, 30'th Jan 2025
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
11:51am, Thursday, 30'th Jan 2025
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their f
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
07:15am, Wednesday, 15'th Jan 2025
Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
01:13am, Tuesday, 07'th Jan 2025
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduc
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
12:16pm, Thursday, 19'th Dec 2024
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their f
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
08:00am, Tuesday, 03'rd Dec 2024
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose App
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
07:30am, Tuesday, 12'th Nov 2024
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Brea
